SEC Form 4 · accession 0001209191-15-028590
Revance Therapeutics, Inc. · RVNC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Curtis Ruegg
Officer — EVP, Technical Operations
Period of report
Mar 19, 2015
Accepted (ET)
Mar 23, 2015 · 6:09 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001479290
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 19, 2015 | M | 500 | $6.60 | A | 19,837 | D | |
| Common Stock | Mar 19, 2015 | S | 500 | $20.00 | D | 19,337 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $6.60 | Mar 19, 2015 | M | 500 | D | — | May 15, 2016 | Common Stock | 500 | 1,003 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 15, 2014.
- F2The Option is fully vested as of May 16, 2010.